financetom
Business
financetom
/
Business
/
Kimbell Royalty Partners Shares Rise After Posting Higher Q1 Net Income, Revenue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kimbell Royalty Partners Shares Rise After Posting Higher Q1 Net Income, Revenue
May 26, 2025 4:14 AM

09:51 AM EDT, 05/08/2025 (MT Newswires) -- Kimbell Royalty Partners LP ( KRP ) shares were up more than 10% in early Thursday trading after the company reported Q1 net income of $0.20 per diluted unit, up from $0.04 a year earlier.

Analysts polled by FactSet expected $0.11.

Revenue for the quarter ended March 31 was $84.2 million, up from $82.2 million a year earlier.

Analysts surveyed by FactSet expected $85.3 million.

Price: 13.11, Change: +1.23, Percent Change: +10.35

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Oceanagold Completes IPO, Raises Us$106M For The Sale Of 20% Interest In Ogpi
BRIEF-Oceanagold Completes IPO, Raises Us$106M For The Sale Of 20% Interest In Ogpi
May 13, 2024
May 13 (Reuters) - OceanaGold Corp ( OCANF ): * OCEANAGOLD COMPLETES IPO, RAISES US$106M FOR THE SALE OF 20% INTEREST IN OGPI Source text for Eikon: Further company coverage: ...
UBS Makes Nearly $5 Billion in AT1 Debt Available for Equity Conversion
UBS Makes Nearly $5 Billion in AT1 Debt Available for Equity Conversion
May 13, 2024
07:58 AM EDT, 05/13/2024 (MT Newswires) -- UBS (UBS) said Monday that roughly $5 billion worth of Additional Tier 1 bonds have been made available for equity conversion. Price: 30.00, Change: +0.30, Percent Change: +1.01 ...
Merck Halts Drug Combination Arm of Study Testing Potential Melanoma Treatment
Merck Halts Drug Combination Arm of Study Testing Potential Melanoma Treatment
May 13, 2024
07:58 AM EDT, 05/13/2024 (MT Newswires) -- Merc (MRK) said Monday it halted the vibostolimab and pembrolizumab combination arm of its phase 3 trial evaluating investigational adjuvant treatments for patients with resected high-risk melanoma. Data so far showed that the primary endpoint of recurrence-free survival met the pre-specified futility criteria. However, the drug company said that a higher rate of...
ESR says has investor group's proposal to take it private
ESR says has investor group's proposal to take it private
May 13, 2024
HONG KONG, May 13 (Reuters) - Hong Kong-listed real estate fund manager ESR Group ( ESRCF ), which halted trading in its shares on Monday, said in an exchange filing that a group of investors has proposed to take the company currently valued at $5.4 billion private. ESR, which is backed by U.S. private equity firm Warburg Pincus LLC, said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved